Categories
Integra LifeSciences is removing certain lots of Microsensor and Cerelink ICP Kits with potential corrosion stains on the included Tuohy Needle.
Categories
Endovascular Graft Recall: Cook Medical Removes Zenith Alpha 2 Thoracic Endovascular Graft
Cook Medical is removing certain ZENITH ALPHA 2 THORACIC ENDOVASCULAR GRAFT proximal components because PTFE scrapings may enter the stent graft during deployment.
Categories
MRI System Correction: Siemens Healthineers Issues Correction for 3 Tesla MRI Systems
Siemens Healthineers is correcting 3 Tesla MRI systems including MAGNETOM and BioGraph mMR due to the potential for ice blockage in the magnet venting system
Categories
Catheter Mount Recall: Draeger Removes ErgoStar Catheter Mounts
Drager is removing affected ErgoStar Cather Mounts due to cracks in the hose.
Categories
Cardiac Cannula Recall: Medtronic Removes DLP Left Heart Vent Catheter
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Categories
Microbore Extension Set Recall: B. Braun Medical Inc. Removes Microbore Extension Sets
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Categories
Infusion Pump Correction: Baxter Issues Correction for Novum IQ Large Volume Pumps
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Categories
FDA Grants Two National Priority Vouchers
FDA Grants Two National Priority Vouchers
http://www.fda.gov/news-events/press-announcements/fda-grants-two-national-priority-vouchers
Categories
FDA Explores New Contracting Approach to Advance Public Health Innovation
FDA Explores New Contracting Approach to Advance Public Health Innovation
http://www.fda.gov/news-events/press-announcements/fda-explores-new-contracting-approach-advance-public-health-innovation
Categories
Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication
Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in thromboembolic